Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Last updated: October 19, 2018
Sponsor: Novartis Pharmaceuticals
Overall Status: Completed

Phase

4

Condition

Glaucoma

Treatment

N/A

Clinical Study ID

NCT03150160
CQVJ499A2404
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from further IOP lowering.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Sign written informed consent

  • Diagnosed with normal tension glaucoma

  • Intraocular pressure measurements in at least 1 eye as specified in the protocol

  • Willing and able to attend all study visits

Exclusion

Exclusion Criteria:

  • History of hypersensitivity to any of the study drugs

  • Use of medications prohibited by the protocol

  • Pregnant or nursing

  • Of child-bearing potential unless using contraception, as specified in the protocol

  • Any form of glaucoma other than open angle glaucoma in either eye

  • Chronic, recurrent or severe inflammatory eye disease

  • Ocular trauma or surgery within the past 6 months in either eye; ocular infection orlaser surgery within the past 3 months in either eye (all from screening)

  • Conditions which would make the patient, in the opinion of the Investigator,unsuitable for the study.

Study Design

Total Participants: 1
Study Start date:
September 21, 2017
Estimated Completion Date:
December 04, 2017

Study Description

This study was prematurely terminated due to administrative reasons and not due to any safety or efficacy concerns.

Connect with a study center

  • Novartis Investigative Site

    Drummondville, Quebec J2C 2C4
    Canada

    Site Not Available

  • Novartis Investigative Site

    Busan, 49241
    Korea, Republic of

    Site Not Available

  • Novartis Investigative Site

    Seoul, 03080
    Korea, Republic of

    Site Not Available

  • Novartis Investigative Site

    Kaohsiung, 80756
    Taiwan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.